These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Listed as ongoing, but also has a completion date and reported results 2004-002509-63 A double blind, randomised, placebo controlled, parallel group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis 2005-12-20 bad-data
Listed as ongoing, but also has a completion date and reported results 2004-002530-20 A double blind, randomised, placebo controlled, parallel group study of Sativex in the treatment of subjects with pain due to diabetic neuropathy 2006-06-08 bad-data
Listed as ongoing, but also has a completion date and reported results 2004-002531-32 A double blind, randomised, placebo controlled, parallel group study of Sativex, in the treatment of subjects with peripheral neuropathic pain associated with allodynia 2006-10-18 bad-data
Ongoing, reported early 2004-004395-36 A Multi-Centre, Open Label, Follow-on Study to Assess the Maintenance of Effect, Tolerance and Safety of Sativex in the Treatment of Subjects with Neuropathic Pain not-yet-due
Listed as ongoing, but also has a completion date and reported results 2005-005265-11 A double blind, randomised, placebo controlled, parallel group study of Sativex® when added to the existing treatment regimen, in the relief of central neuropathic pain in subjects with multiple scler... 2008-04-30 bad-data
Ongoing 2006-001598-10 A double blind, randomised, placebo controlled, parallel group study of Sativex® in the treatment of subjects with pain due to diabetic neuropathy not-yet-due
Not reported Terminated 2006-003655-20 A double blind, randomised, placebo controlled, parallel group study of Sativex® when added to the existing treatment regimen, in the relief of post-herpetic neuralgia. 2008-10-07 due-trials
Listed as ongoing, but also has a completion date and reported results 2006-005910-11 A two-phase Phase 3 study of the safety and efficacy of Sativex®, in the symptomatic relief of spasticity in subjects with spasticity due to multiple sclerosis: Phase A – single blind response assessm... 2009-01-30 bad-data
Reported results 2007-002138-13 A placebo controlled, parallel group, randomised withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term GW-1000-02 (Sativex®). 2009-01-16 due-trials
Listed as ongoing, but also has a completion date and reported results 2007-005225-30 A double blind, randomized, placebo controlled, parallel group dose range exploration study of Sativex® in relieving pain in patients with advanced cancer, who experience inadequate analgesia during o... 2041-01-04 bad-data
Reported results 2009-016064-36 A double blind, randomized, placebo-controlled, parallel group study of Sativex oromucosal spray (Sativex®; Nabiximols) as adjunctive therapy in relieving uncontrolled persistent chronic pain in patie... 2015-07-02 due-trials
Reported results 2009-016065-29 A double blind, randomized, placebo-controlled, parallel group study of Sativex oromucosal spray (Sativex®; Nabiximols) as adjunctive therapy in relieving uncontrolled persistent chronic pain in patie... 2014-11-24 due-trials
Listed as ongoing, but also has a completion date and reported results 2009-016529-32 A multicenter, non-comparative, open-label extension study to assess the long term safety of Sativex oromucosal spray (Sativex®; Nabiximols) as adjunctive therapy in patients with uncontrolled persist... 2017-01-27 bad-data
Ongoing, reported early 2009-017080-41 A randomised, partially-blind, placebo-controlled, pilot, dose-ranging study to assess the effect of cannabidiol (CBD) on liver fat levels in subjects with fatty liver disease. not-yet-due
Not reported 2010-020458-33 A randomised, double blind, placebo controlled, parallel group, pilot study of 1:1 and 20:1 ratio of formulated GW42003: GW42004 plus GW42003 and GW42004 alone in the treatment of dyslipidaemia in sub... 2012-02-07 due-trials
Listed as ongoing, but also has a completion date and reported results 2010-022905-17 A two-part, placebo-controlled, study of the safety and efficacy of Sativex oromucosal spray (Sativex®; Nabiximols) as adjunctive therapy in relieving uncontrolled persistent chronic pain in patients ... 2015-07-10 bad-data
Reported results Terminated 2011-000180-28 A randomised, double-blind, placebo-controlled parallel group, pilot study of 40:1 ratio of formulated GWP42003 : GWP42004 in the treatment of iatrogenic weight gain and dyslipidaemia associated with ... 2012-10-01 due-trials
Reported results 2011-000926-31 A Multicentre, Double-blind, Randomised Parallel Group, Placebo- controlled Study of the Effect of long-term treatment with Sativex on Cognitive Function and Mood of Patients with Spasticity due to Mu... 2013-05-13 due-trials
Reported results 2011-003208-19 A randomised, double-blind, placebo-controlled parallel group, pilot study of GWP42003 in the symptomatic treatment of ulcerative colitis. 2014-08-04 due-trials
Reported results 2012-003771-18 The efficacy, safety and tolerability of Sativex as an adjunctive treatment to existing anti-spasticity medications in children aged 8 to 18 years with spasticity due to cerebral palsy or traumatic ce... 2017-03-23 due-trials
Reported results 2013-000212-22 A double-blind, randomised, placebo-controlled, parallel group study of GWP42003 as adjunctive therapy in the first line treatment of schizophrenia or related psychotic disorder 2015-01-08 due-trials
Reported results 2013-001140-61 A randomised, double blind, placebo controlled, parallel group, dose ranging study of GWP42004 as add on to metformin in the treatment of participants with Type 2 diabetes. 2015-12-29 due-trials
Reported results 2014-000995-24 A double-blind, placebo-controlled two-part study to investigate the dose-ranging safety and pharmacokinetics, followed by the efficacy and safety of cannabidiol (GWP42003-P) in children and young adu... 2016-11-26 due-trials
Ongoing 2014-001834-27 An open label extension study to investigate the safety of cannabidiol (GWP42003-P; CBD) in children and adults with inadequately controlled Dravet or Lennox-Gastaut Syndromes not-yet-due
Listed as ongoing, but also has a completion date and reported results 2014-002594-11 A double blind, randomized, placebo-controlled, two-part study to investigate the pharmacokinetics, followed by efficacy and safety of GWP42006 as add-on therapy in patients with inadequately controll... 2017-09-01 bad-data
Not reported 2014-002939-34 A randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of cannabidiol (GWP42003-P) in children and young adults with Dravet syndrome. 2018-04-09 due-trials
Reported results 2014-002940-42 A randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of cannabidiol (GWP42003-P; CBD) as adjunctive treatment for seizures associated with Lennox-Gastaut syndrom... 2016-05-02 due-trials
Reported results 2014-002941-23 A randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of cannabidiol (GWP42003-P; CBD) as adjunctive treatment for seizures associated with Lennox- Gastaut syndro... 2016-02-26 due-trials
Reported results 2014-002942-33 A phase 2, double-blind, randomized, placebo-controlled study to investigate possible drug-drug interactions between clobazam and cannabidiol (GWP42003-P) 2017-06-07 due-trials
Other 2015-002154-12 A double-blind, randomized, placebo-controlled study to investigate the efficacy and safety of cannabidiol (GWP42003-P, CBD) as add-on therapy in patients with tuberous sclerosis complex who experienc... not-yet-due
Ongoing 2015-002939-18 A phase 2, double-blind, randomized, placebo-controlled pharmacokinetic trial in two parallel groups to investigate possible drug- drug interactions between stiripentol or valproate and GWP42003-P in ... not-yet-due
Completed, but no date 2015-004904-50 A randomized, double-blind, placebo-controlled trial to investigate the efficacy and safety of Cannabidiol (GWP42003-P) in infants with Infantile Spasms following an initial open label pilot study. bad-data